Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and... see more

TSXV:THRM - Post Discussion

Therma Bright Inc > Please curb your enthusiasm...
View:
Post by thrmadmin on Jan 11, 2022 2:56pm

Please curb your enthusiasm...

To all shareholders.  Firstly thank you for your continued support and patience (from most of you).  I say "mosdt of you" because there are a number of peple contacting the Clinical Performance Study's clinics, investigator and staff.  Please refrain from doing so as they are the ones driving this effort for the betterment of our business and you, the shareholders.  As well intentioned as these efforts are, they are counter intuitive to expediting the process.  We will notify the market once the study is complete.  Again, thank you for your continued support.
Comment by Smokey1958 on Jan 11, 2022 3:10pm
WHO in their right mind thought this was a good idea? It's either well intentioned, but incredibly naive investors or bashers (and trolls) trying to get just this kind of rise out of management. Firat of all you better consider investing in GICs if you thought those involved with the clinical trials were going to pass along ANY information ...you should be embarrassed. If you're a basher  ...more  
Comment by Boudi1959 on Jan 11, 2022 3:15pm
check with some idiots here whom just happened to know about the tweet today when we knew about it 2 weeks ago. It is easy to figure them out, shamefull and losers
Comment by birch1 on Jan 11, 2022 3:18pm
yeah, agreed, only puts their back up and makes it take longer.
Comment by Kaiser on Jan 11, 2022 3:46pm
This post has been removed in accordance with Community Policy
Comment by hk1966 on Jan 11, 2022 3:18pm
Thank you Admin however much of this could have been avoided with a proactive statement from mgmt along the lines of "the study is in progress still and we will update everyone once completed package has been sent into the FDA for review. 
Comment by Smokey1958 on Jan 11, 2022 3:44pm
Agreed, hk, which should have come based on the info from Cote's post on the updated overview from clinicaltrials.gov! Unfortunately that didn't happen. That does not absolve those who thought this was in anyway a means to circumvent that fact. It was obviously deemed extreme and critical enough for the liason of the clinical trials to contact THRM management. Hopefully everyone has ...more  
Comment by Boudi1959 on Jan 11, 2022 4:41pm
It was me who put the update way before Cote, be fair Smokey and honest
Comment by Avrgjoeinvested on Jan 11, 2022 3:27pm
Thx for the update Mr.Fia My question Why aren't we getting any updates in comparison against the Brasilian clinical studie completed last year before final submission to the FDA EUA I would assume this would be considered as material information for your shareholders. Wouldn't it be? Thanks in advance for your consideration and feedback. Best regards
Comment by dmshediac on Jan 11, 2022 3:31pm
This post has been removed in accordance with Community Policy
Comment by dmshediac on Jan 11, 2022 3:36pm
This post has been removed in accordance with Community Policy
Comment by TuTomek on Jan 13, 2022 9:08am
Another Thrmsday today and no news. We refrain from contacting the Clinical Performance Study's clinics, but Rob please give use anything! :) Just kidding. I'll wait patiently.......................................................... GLTA!
Comment by 13X2413 on Jan 13, 2022 10:37am
Does this thing still have a heartbeat? No action here whatsoever. 
Comment by 13X2413 on Jan 13, 2022 10:59am
Another company leaving us in the dust. Which one are we, the turtle or the hare. Quite obvious.  Quebec's Health Ministry states it has reached an agreement with locally-based MedSup Medical to produce more than 70 million rapid tests in the coming months.
Comment by spygate on Jan 13, 2022 11:34am
Leaving us in the dust? Maybe read the whole article 'The Quebec government notes the company is a medical supply wholesaler certified by Health Canada and the rapid test project will only go ahead after proper authorization by public health bodies'
Comment by Smokey1958 on Jan 13, 2022 12:18pm
Low volume, day traders playing ....albeit with little interest. That's a great development. No action is a positive sign at this stage. ALL the outstanding shares are being held patiently because no one wants to miss out when the FDA EUA NR takes place. You would have cause to worry if millions of shares were on the ASK right now. Nobody buying, nobody SELLING! AcuVid has well established ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities